329. Aniridia Clinical trials / Disease details

Clinical trials : 3 / Drugs : 2 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04117880 (ClinicalTrials.gov)	December 31, 2018	19/9/2019	A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia	Nonsense Mutation Aniridia: An Ataluren (PTC124) Phase 2 Extension Study	Aniridia	Drug: Ataluren	PTC Therapeutics	NULL	Withdrawn	2 Years	N/A	All	0	Phase 2	NULL
2	NCT02647359 (ClinicalTrials.gov)	January 31, 2016	29/12/2015	Study of Ataluren in Participants With Nonsense Mutation Aniridia	STAR: A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia	Aniridia	Drug: Ataluren;Drug: Placebo	PTC Therapeutics	NULL	Completed	2 Years	N/A	All	39	Phase 2	United States;Canada
3	JPRN-UMIN000002948	2013/04/01	29/12/2009	Cultivated epithelial sheet transplantation for corneal epithelial stem cell deficiency		a) Steven's Johnson Syndromeb) Ocular cicatricial pemphigoidc) Chemical/ Thermal Burns of the Cornead) Gelatinous Drop Like Dystrophye) Salzmann Corneal Degenerationf) Congenital Aniridia	Corneal epithelial sheet transplantation Cultivated eptihealial sheet transplantation will be perfored in the surgical department of Keio University Hospital. Simultaneous lamellar keratoplasty will be allowed. Surgical procedure involves removal of all pannus and abnormal epithelial tissue, the use of 0.04% mitomycin C to prevent fibrosis, and transplantation of the cultivated sheet.	Department of Ophthalmology, Keio University School of Medicine	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	5	Not selected	Japan